Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

SOPHiA GENETICS (SOPH) EBITDA Margin (2020 - 2025)

SOPHiA GENETICS's EBITDA Margin history spans 6 years, with the latest figure at 85.3% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 3426.0% to 85.3% in Q4 2025 year-over-year; TTM through Dec 2025 was 91.76%, a 250.0% decrease, with the full-year FY2025 number at 91.76%, down 3011.0% from a year prior.
  • EBITDA Margin hit 85.3% in Q4 2025 for SOPHiA GENETICS, up from 91.78% in the prior quarter.
  • Over the last five years, EBITDA Margin for SOPH hit a ceiling of 51.04% in Q4 2024 and a floor of 230.37% in Q1 2022.
  • Historically, EBITDA Margin has averaged 131.47% across 5 years, with a median of 115.78% in 2024.
  • Biggest five-year swings in EBITDA Margin: crashed -7380bps in 2022 and later surged 10147bps in 2023.
  • Tracing SOPH's EBITDA Margin over 5 years: stood at 192.09% in 2021, then surged by 41bps to 112.69% in 2022, then skyrocketed by 37bps to 71.25% in 2023, then grew by 28bps to 51.04% in 2024, then plummeted by -67bps to 85.3% in 2025.
  • Business Quant data shows EBITDA Margin for SOPH at 85.3% in Q4 2025, 91.78% in Q3 2025, and 100.92% in Q2 2025.